Intuitive Surgical and Computer Motion Merge to Create Concentrated Robotics Play

Tired of fighting each other in court, the two leading robotics companies have decided to render their IP differences moot through a merger.

For many companies trying to get innovative technology accepted in the marketplace, intellectual property becomes a critical battleground. But when it becomes the primary battleground, IP litigation can divert and distort the companies from their main goal: gaining adoption for their technology. That, at least, is what happened in surgical robotics, a highly promising, but to date poorly penetrated innovation. And now, tired of fighting each other in court, the two leading robotics companies, Sunnyvale, CA-based Intuitive Surgical Inc. and Santa Barbara, CA-based Computer Motion Inc. , have decided to render their IP differences moot through a merger of the two companies [See Deal].

Discussing the deal, Lonnie Smith, Intuitive's CEO who will run the combined company, noted that "Clearly, we were both pouring...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Innovation

More from In Vivo

EU Medtech Outlook: The View From MedTech Europe Experts

 
• By 

MedTech Forum 2025 was less MDR-focused than in previous years, as macro issues and exogenous threats were forced further into the center of medtech business thinking.

‘Confident In Lorundrostat’s Promise’: Mineralys CEO Talks Trials And Next Steps

 

In a conversation with In Vivo, CEO Jon Congleton discusses Mineralys’s data-rich journey toward an NDA filing, the significance of recent trial wins and how its candidate may offer a dual benefit in blood pressure and renal protection.

BioBytes: Qubit Pharmaceuticals Unveils Quantum AI Model For Drug Discovery

 
• By 

Qubit Pharmaceuticals and Sorbonne University launched a quantum AI model that could slash drug synthesis requirements and enable exploration of previously undruggable targets.